Disc Medicine, Inc. (IRON) Form 8-K — Oct 22, 2026
Disc Medicine priced an upsized underwritten public offering of 6,000,000 shares at $75.00 per share, raising approximately $450 million gross, with a 30-day option for 900,000 additional shares. The offering was originally announced at $350 million and was upsized, with Jefferies, Leerink, Morgan Stanley and Cantor as book-running managers. Net proceeds are expected to be about $422.4 million, or about $485.9 million with the full greenshoe. Combined with its preliminary $682.8 million in cash as of September 30, 2026, the company says it is funded into 2030, excluding any revenue from bitopertin if approved for EPP and XLP.
Key figures
- Cash Position
- 682800000
- Gross Proceeds
- 450000000
- Offering Price
- 75
- Shares Offered
- 6000000
- Shares Outstanding
- 0
- Cash runway
- into 2030
- Lockup days
- 45
- Greenshoe shares
- 900000
- Net proceeds estimated
- 422400000
- Net proceeds full greenshoe
- 485900000
- Underwriter purchase price per share
- 70.5
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.